PREVENTION OF EVENTS WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS

使用血管紧张素转换酶抑制剂预防事件

• 批准号: 6276139
• 负责人: GEORGE W. VETROVEC
• 金额: $ 3.31万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276139
• 关键词: cardiovascular disorder chemotherapy; cardiovascular pharmacology; clinical research; clinical trials; coronary artery; coronary disorder; disease /disorder proneness /risk; enzyme inhibitors; heart disorder chemotherapy; heart function; heart pharmacology; heart ventricle; human mortality; human subject; human therapy evaluation; myocardial infarction; peptidyl dipeptidase A

To determine whether the addition of angiotensin converting enzyme(ACE) inhibitor to standard therapy in patients with known coronary artery disease and preserved left ventricular function will reduce the risk of cardiovascular mortality or of experienceing a myocardial infarction.

为了确定是否添加血管紧张素转换酶（ACE） 已知冠状动脉狭窄患者标准治疗的抑制剂 疾病和保留的左心室功能将降低 心血管死亡率或经历心肌梗死。